Prof. Dr. Olaf Witt

Office DKFZ:
Phone: +49 6221 423570
Office Department of Pediatric Oncology:
Phone: +49 6221 564555



Develop better therapies ...


for children with neuronal cancers.

Clinical Cooperation Unit Pediatric Oncology


Our group/department has:

  • Described novel druggable oncogenic pathways involving HDACs isoforms (Fabian et al. Cancer Res 2014, Oehme et al. PNAS 2013, Lodrini et al. Nucl Acid Res 2013, Milde et al Clin Cancer Res 2010, Oehme et al. Clin Cancer Res 2009) resulting in phase I/II clinical trial of an HDAC inhibitor in children (Witt et al., Klin Padiatr 2012).
  • Developed new pediatric brain tumor models and biomarkers (Milde et al., J Neurooncol 2012, Milde et al., Brain Pathol 2012, Milde et al. Acta Neuropathol 2011, Witt H et al, Cancer Cell 2011)
  • Initiated and currently coordinate phase I-III clinical trials including the first multicenter, nationwide study on personalized pediatric oncology (INFORM) and the Pediatric Targeted Therapy (PTT) program for individualized pathway analysis in relapsed pediatric tumors (

2010 – 2013

  • Oehme I, Linke JP, Böck BC, Milde T, Lodrini M, Hartenstein B, Wiegand I, Eckert C, Roth W, Kool M, Kaden S, Gröne HJ, Schulte JH, Lindner S, Hamacher-Brady A, Brady NR, Deubzer HE, Witt O. Histone deacetylase 10 promotes autophagy-mediated cell survival.
    Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):E2592-601
  • Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, Schulte JH, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler MU, Kulozik AE, Westermann F, Witt O, Deubzer HE. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
    Nucleic Acids Res. 2013 Jul;41(12):6018-33.
  • Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I, Lodrini M, Gröne HJ, Benner A, Brüstle O, Gilbertson RJ, von Deimling A, Kulozik AE, Pfister SM, Martin-Villalba A, Witt O. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol. 2011 Nov;122(5):637-50.
  • Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, Deubzer HE, Lodrini M, Taylor MD, von Deimling A, Pfister S, Witt O. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010 Jun 15;16(12):3240-52.
  • Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O. Histone deacetylase 8 in neuroblastoma tumorigenesis.
    Clin Cancer Res. 2009 Jan 1;15(1):91-9.
  • BMBF - MYC-NET, 0316076B - TP4: Validation of mathematical models in preclinical models
  • BMBF – NGFNplus, 01GS0896 –TP 14: Neuroblastoma therapy by targeting class I histone deacetylases. 2008-2013
  • Deutsche Kinderkrebsstiftung - A 2007/26 DKS 2009.16: Phase I/II study of vorinostat in children with relapsed or refractory solid tumor, leukemia, and lymphoma; 2011-2015